Table 2.
Summary of retrospective studies reporting on bedaquiline‐containing treatment for MDR‐TB patients
| Corresponding author, countries, publication year | No. of cases in efficacy assessment/no. of cases in the study | No. (%) pre‐XDR‐TB cases | No. (%) XDR‐TB cases | Regimen design | No. (%) of cases taking LZD | No. (%) cases HIV‐infected | The median time to culture conversion (days) | Sputum culture conversion at week 24 | Treatment outcome evaluation |
|---|---|---|---|---|---|---|---|---|---|
| Jérôme Robert, France, 2015 | 29/35 | 14 (40%) | 19 (54%) | A DST‐individualized regimen including a median of five effective drugs. Nine patients took surgical treatment. | 33 (94%) | 0 (0%) | 85 | 28/29 (97%) | Not specified. Only early efficacy assessment. |
| Alena Skrahina, Belarus, 2016 | 197/197 | 59 (29.9%) | 128 (65.0%) | Not specified | Not specified | Not specified | Not specified | 186/197 (94.4%) | Not specified. Only early efficacy assessment. |
| Christoph Lange, Germany, 2017 | 20/30 | 9 (30%) | 15 (50%) | A DST‐individualized regimen of a median of six effective drugs. BDQ was started within 1 month of treatment start. | Not specified | Not specified | 49 | 20/20 (100%) | Not specified. Only early efficacy assessment. |
| Lorenzo Guglielmetti, France, 2017 | 41/45 | 17 (38%) | 24 (53%) | A DST‐individualized regimen of a median of seven effective drugs. Of note, 33 were treated BDQ treatment >190 days. | 43 (95.6%) | 2 (4.4%) | 89 | 40/41 (97.6%) | 36 (80%) had favorable outcome, 5 were lost to follow‐up, 3 died, and acquired BDQ resistance. |
| Jai. Mullerpattan, India, 2017 | 17/20 | 7 (35%) | 13 (65%) | A regimen of a median of six drugs. | 20 (100%) | 1 (5%) | 81 | 11/17 (64.7%) | 11 cured, 7 failed, 2 still on treatment. |
| Yong‐Soo Kwon, South Korea, 2018 | 36/39 | 25 (64.1%) | 9 (23.1%) | The median duration of BDQ was 323 days. | 17 (44%) | Not specified | 84 | 24/36 (66.7%) | Not specified. 5/39 cases discontinued treatment before 6 months. |
| Giovanni Battista Migliori, multi‐countrya, 2017 | 247/428 | Not specified | 195 (45.6%) | A DST‐individualized regimen. | 351 (82%) | 94/425 (22.1) | 60 | Not specified | 51/428 discontinued BDQ. Of note, 154/247 (62.4%) cured, 22 completed, 33 died, 18 default, 19 failed. |
MDR‐TB = multidrug‐resistant tuberculosis; pre‐XDR‐TB = pre‐extensively drug‐resistant tuberculosis; XDR‐TB = extensively drug‐resistant tuberculosis; LZD = linezolid; BDQ = bedaquiline.
a
This study enrolled patients from 15 countries in Africa, Asia, Western and Eastern Europe, Oceania, and Southern America (Argentina, Australia (Victoria State), Belarus, Belgium, Greece, India, Italy, the Netherlands, Peru, Portugal, Russian Federation (Arkhangelsk and Moscow city), South Africa, Spain, Sweden, and United Kingdom).